E.R.Squibb and Sons Llc v. Union of India
Case brief
What is this about?
Madras High Court (N. Senthilkumar, J.), W.P. No.8451 of 2023, pronounced 05.01.2026. Patentees E.R. Squibb & Sons LLC and Ono Pharmaceuticals Co. Ltd. sought certiorarified mandamus to quash the Opposition Board recommendation dated 31.01.2023 in the post-grant opposition (Section 25(2), Patents Act 1970) filed by Zydus Healthcare Limited against Indian Patent IN340060 ('Human Monocolonal Antibodies to Programmed Death I (PD-1) for use in Cancer'; application 5057/CHENP/2007, national phase of PCT/JP2006/209606), alleging non-consideration of patentee evidence under Rules 57-60, Patents Rules 2003. Issues: maintainability of a writ against a mere Opposition Board recommendation; prejudice. Held: writ not maintainable/premature — recommendation not binding; Controller decides under Section 25(4) after Rule 62(1) hearing; objections including non-consideration of evidence raisable there; appeal under Section 117A; reconstitution precedents (Ashok Leyland — consent; Optimus Drugs — post-recommendation evidence) distinguished. Petition dismissed, connected W.M.Ps. closed, no costs.